Bo and I discuss some of the leading candidates for extending both human lifespan and “health-span”, including metformin, nicotinamide riboside & nicotinamide mononucleotide, and caloric restriction. We also chat about some of the companies working in this area, as well as novel business models that may or may not be a strategy to enable rigorous research of something as difficult to study as human lifespan.
All content for Wired to be Weird is the property of Ian McLaughlin & Bo Allen and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Bo and I discuss some of the leading candidates for extending both human lifespan and “health-span”, including metformin, nicotinamide riboside & nicotinamide mononucleotide, and caloric restriction. We also chat about some of the companies working in this area, as well as novel business models that may or may not be a strategy to enable rigorous research of something as difficult to study as human lifespan.
In preparation for the upcoming mid-term elections in the United States (REMEMBER TO VOTE ON NOVEMBER 6TH !), Bo and I chat about how much of a person’s politics are inherited genetically from their parents, as well as some companies that are entirely devoted to trying to make you vote in a certain way. I learned quite a bit prepping for this conversation, and suffice it to say that I was pretty surprised with what I learned.
Note about the recording: if you can’t tell, we’re using a new audio set-up (thank you Patreon & Twitter supporters!!!). While we have gotten rid of some of the ambient noise – at least as much noise as you can in a Philly apartment – we’re clearly lacking pop-filters on this recording. So, apologies for the heavy Ps and Bs on this one; a pop-filter has been ordered.
Wired to be Weird
Bo and I discuss some of the leading candidates for extending both human lifespan and “health-span”, including metformin, nicotinamide riboside & nicotinamide mononucleotide, and caloric restriction. We also chat about some of the companies working in this area, as well as novel business models that may or may not be a strategy to enable rigorous research of something as difficult to study as human lifespan.
